Agenus and Noetik Link AI Pathology Analysis to CRC Treatment Outcomes
Event summary
- Agenus and Noetik presented ASCO 2026 data showing AI analysis of routine pretreatment tumor pathology images can predict clinical outcomes for BOT+BAL in MSS metastatic CRC.
- Noetik’s TARIO-2 model demonstrated statistically significant predictive performance for best overall response and overall survival in MSS mCRC without active liver metastases.
- The analysis included 113 efficacy-evaluable patients treated with BOT+BAL in the C-800-01 Phase 1b trial.
- TARIO-2 outperformed benchmark pathology foundation models in predicting clinical endpoints in the MSS mCRC cohort.
- Prospective validation of TARIO-2 as a practical, image-based biomarker strategy is the next critical step.
The big picture
Agenus and Noetik’s collaboration highlights the growing role of AI in deciphering complex tumor microenvironments, potentially unlocking new patient stratification strategies. This approach could be particularly impactful in tumor types like MSS CRC, which have historically shown limited response to conventional immunotherapies. The ability to extract actionable insights from routine pathology images represents a significant step toward more personalized cancer treatment.
What we're watching
- Validation Pathway
- Whether prospective validation of TARIO-2 can confirm its predictive capabilities and support regulatory approvals.
- Clinical Adoption
- The pace at which AI-based pathology analysis integrates into standard clinical practice for patient stratification.
- Competitive Positioning
- How Agenus leverages this data to differentiate BOT+BAL in the crowded immuno-oncology market.
Related topics